North America is the key growth
engine in the global hemostasis diagnostics market
Regional segmentation of the Hemostasis
Diagnostic Market by Coherent Market Insights comprises North America,
Europe, Asia Pacific, Latin America, Middle East, and Africa. According to the
Centre for Disease Control and Prevention in 2015, the number of people with
hemophilia in the U.S. is estimated to be 20,000.
This positions North America as
the most dominant region in the global hemostasis diagnostics market, owing to
the rise in installed instruments leading to higher sales of reagents and
support services. According to The European National Registry of Congenital
Coagulopathies in 2017, the number of people identified with hemostasis has
increased from 7000 in 2000 to over 11,000 in 2015.
Therefore, the European market is
expected to grow steadily boosting the demand for hemostasis diagnostics.
Significant growth of markets in India, China, and Brazil is registering due to
the rise in health care expenditure, higher affordability, improving technical
capabilities and economic development. These markets are expected to attract
global companies for capitalizing on the hemostasis diagnostics market
opportunities.
Hemostasis diagnostics help
identify the hemostatic defects that cause excessive bleeding. Hemostasis is a
process of slowing and stopping the blood flow to initiate wound healing after
a vascular injury and is the key procedure acting in the first line of action
adopted by the body. During the process, blood changes its form from the fluid
state to the gelatinous state. Hemostasis is maintained in the body via three
mechanisms namely vasoconstriction, platelet plug formation, and blood
coagulation.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/434
The diagnosis helps predict the
cause of excessive bleeding during the surgery, identifies hemostatic defects
in patients with a history of excessive bleeding. Based on the research
articles published by medical experts, the appropriate therapy to treat
hemorrhage can be administered of fresh frozen plasma for coagulation defects,
Von Willebrand factor concentrates for platelet function defects or
antifibrinolytic agents for systemic fibrinolysis.
Rising prevalence of hemophilia
drives the hemostasis diagnostics market globally
The critical nature of the
procedure in the field of medicine and healthcare has gained a prominent
position in the hemostasis diagnostics market. According to the National
Hemophilia Foundation in 2012, the global incidence of hemophilia is estimated
to be 400,000 people. The rise in the prevalence of genetically inherited
disorders such as hemophilia, an increase in the number of surgeries and trauma
patients, the surge in the usage of recombinant products are the collective
factors driving the global market.
The growing technological
advances in molecular diagnostics, inexpensive and biodegradable diagnostic
products, chromogenic substrates, monoclonal antibodies, immunoassays,
laboratory automation is estimated to radically change the Hemostasis diagnostics
market over the following five years.
U.S. Beckman Coulter holds over
half the U.S. market for Hematology devices
Key players operating in the
market are HORIBA, Ltd., Abbott Laboratories, Siemens AG, and Bio-Rad
Laboratories, Inc. The high and low-end analyzers provided by U.S. Beckman
Coulter meet the needs of all hematology testing environment. Other vendors who
have adopted ideal product models, business expansion and market appeal
strategies are Becton, Dickinson & Company, Grifols S.A, Alere, Inc., F.
Hoffmann-La Roche AG, Beckman Coulter Inc. Sekisui, Helena Labor, Chrono-Log,
and Axis-Shield.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/hemostasis-diagnostics-market-434
Key Development
In February 2019, Horiba Medical,
launched their new parameter, Yumizen D-Dimer, for its Yumizen G Hemostasis
range of instruments to diagnose deep vein thrombosis and pulmonary embolism.
In 2017, Werfen and it's
subsidiary Instrumentation Laboratory Company acquired Accriva Diagnostics, to
expand leadership in point of care testing.
In 2016, Siemens Healthineers
launched Sysmex CS-2500 a new mid-volume coagulation analyzer. Which enable
labs to provide quality test results and achieve cost-effective method
consolidation.
In 2015, Roche AG launched the
new lab-coagulation solution, the cobas t 411 analyzer is lab coagulation
system suitable for low volume routine testing (up to 120 samples per day),
with this launch Roche AG expanded their diagnostic portfolio.
In 2014, Sysmex Corporation,
launched LIASAUTO P-FDP hemostasis reagent for automated coagulation analyzers
to determine the status of blood hyperfibrinolysis and hypercoagulable
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/434
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment